Advanced Accelerator Applications is a molecular nuclear medicine (MNM) company that develops and commercializes diagnostic and therapeutic products, including PET and SPECT solutions. The company focuses on molecular imaging and personalized medicines, particularly for treatment of diseases such as cancer. It operates 17 production and R&D facilities across Europe, Israel and North America and has over 270 employees in 10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada). Founded in 2002 and led by CEO Stefano Buono, the company plans to use the new funding for expansion and clinical trials of its MNM portfolio. Financially, Advanced Accelerator Applications expected 2013 revenues of €56.6m (a 27% increase versus 2012) and an EBITDA of €14m (a 49% increase versus 2012). Advanced Accelerator Applications (AAA) develops and commercializes diagnostic and therapeutic applications, with a research focus on molecular imaging and personalized medicines. The company produces PET and SPECT products and pursues radio metabolic therapies and diagnostic agents. AAA intends to use new funds to advance clinical trials across its portfolio, including Lutathera® for diagnosis and treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumours (GEPNETs). It has invested prior proceeds into construction of laboratories and R&D activities. To date the company has raised more than €74m to finance its facilities and research. AAA was founded in 2002 as a spin-off from CERN and is led by CEO Stefano Buono, operating 11 production and R&D facilities in France, Italy, Switzerland, Spain and the USA.

Total raised

$114M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2014